New Delhi, June 26 -- Weight-loss drugs have emerged as one of the biggest healthcare trends worldwide, but India appears to be charting a different course. Despite obesity rates climbing and generic versions of GLP-1 medications becoming significantly more affordable, Indian consumers are not adopting these treatments as quickly as many expected.

Zerodha co-founder Nithin Kamath recently highlighted the trend, saying he was surprised that sales of generic GLP-1 drugs had not taken off after patent expiries made them more accessible. His remarks came in response to a report by The Economic Times, which said that "homegrown drugmakers, which entered the generic semaglutide market with ambitious first-year revenue goals, are quietly paring...